Retatrutide, a groundbreaking dual-acting glucose-dependent incretin analog, represents a significant progression in peptide medicines for the handling of type 2 diabetic conditions and, increasingly, weight issues. Unlike many existing medicinal interventions, retatrutide combines the actions of a GLP-1 receptor activator and a GIP receptor stimul